Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner (Q43596346)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

based on heuristic

inferred from title

author name string

Beatrice M Senn

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Zehra Visram

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Andreas L Meinke

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Christina Neubauer

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dieter Gelbmann

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jan Sinzinger

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Markus Hanner

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Urban Lundberg

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Heike Boisvert

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dieter Reinscheid

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Alexander von Gabain

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Eszter Nagy

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

13 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

4116-4124

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Neonatal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Group B streptococcal disease in UK and Irish infants younger than 90 days

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

First molecular characterization of group B streptococci with reduced penicillin susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Antibiotic resistance patterns in invasive group B streptococcal isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Clinical and economic outcomes for term infants associated with increasing administration of antibiotics to their mothers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Group B streptococcal conjugate vaccine: a timely concept for which the time has come

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Group B Streptococcus: global incidence and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Recent advances in understanding the molecular basis of group B Streptococcus virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

A fibrinogen receptor from group B Streptococcus interacts with fibrinogen by repetitive units with novel ligand binding sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

The fibrinogen receptor FbsA promotes adherence of Streptococcus agalactiae to human epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

BibA Induces Opsonizing Antibodies Conferring In Vivo Protection against Group BStreptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Assembly and role of pili in group B streptococci.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Genome Analysis Reveals Pili in Group B Streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Developmental regulation of the human antibody repertoire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Placental transport of immunoglobulin G.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Delineation of the functional capacity of human neonatal lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Passive immunisation of preterm infants with palivizumab against RSV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Immunological fingerprinting of group B streptococci: From circulating human antibodies to protective antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Identification of a universal Group B streptococcus vaccine by multiple genome screen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Relevance of peptide uptake systems to the physiology and virulence of Streptococcus agalactiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Identification of group B streptococcal Sip protein, which elicits cross-protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Adherence to and invasion of human brain microvascular endothelial cells are promoted by fibrinogen-binding protein FbsA of Streptococcus agalactiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Specific involvement of pilus type 2a in biofilm formation in group B Streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Genomic diversity and evolution within the species Streptococcus agalactiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Rapid detection of the “highly virulent” group B streptococcus ST-17 clone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Invasive group B streptococcal infections in infants, France

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Protective Efficacy of Hybridoma Type-Specific Antibody Against Experimental Infection with Group-B Streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Human monoclonal antibodies to group B streptococcus. Reactivity and in vivo protection against multiple serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Intravenous immunoglobulin for suspected or subsequently proven infection in neonates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.100

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.03.100

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43596346&oldid=2101781683"